Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...
2ALNY : 27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
Fintel on MSN1d
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation
Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...
BioSpace1d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Alnylam price target raised to $345 from $300 at Stifel
Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA ...
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...
Alnylam initiated with a Buy at Redburn Atlantic
Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Business Wire3d
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...
Yahoo Finance3d
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip
Alnylam Pharmaceuticals saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip
Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...
Zacks Investment Research on MSN16h
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...